看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
* a) R9 E7 c' f# f, f7 |. W7 J( [) Z5 w9 m0 [) e6 T9 J8 T
4 m0 x, l, V: U, ]1 a1 P
Currently available feasibility data for possible combination strategies. 3 l* b' n- c$ o: d) T3 p6 E$ d
————————————————————————————————
* |, h- R# U8 `- n' ^) [8 w! j) S) r& F& LCombination Feasibility according to preliminary data Q( j& H) [7 Q/ P* Z
——————————————————————————————————, j2 d5 |: z3 m
Bevacizumab + sorafenib Yes, reduced dose
: M n* S' h% N6 m" FBevacizumab + sunitinib† No
5 t# W: x0 m+ ]) l: RBevacizumab + temsirolimus Yes f( C3 Y0 \" o& U$ @' H2 v7 M
Bevacizumab + everolimus Yes * @ ?& u0 z% o o# T
Sorafenib + sunitinib ? $ Y; j5 L/ ~- p
Sorafenib + temsirolimus Yes, reduced dose
- E- _ o8 h6 }/ L; r5 t$ A7 rSorafenib + everolimus Yes, reduced dose
6 b6 x- }5 c8 M( rSunitinib + temsirolimus† No : B2 H, t2 |$ X, t$ p. k+ P
Sunitinib + everolimus ?
7 x5 F6 c$ z4 ] \Temsirolimus + everolimus ? ) x: z/ v9 ]5 ^' [
————————————————————
6 K8 Y3 t6 y9 G8 A" ]†Led to US FDA warning.1 l: K! a# K% F
?: As yet unattempted combination.
% |5 ?& V3 a. H5 o2 e% i! P! v/ ^ |
显身卡
